Suppliers and packagers for generic pharmaceutical drug: LINAGLIPTIN

LINAGLIPTIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sunshine	LINAGLIPTIN	linagliptin	TABLET;ORAL	208335	ANDA	Sunshine Lake Pharma Co., Ltd.	48792-7865-1	30 TABLET, FILM COATED in 1 BOTTLE (48792-7865-1)	2026-01-01
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0140-30	30 TABLET, FILM COATED in 1 BOTTLE (0597-0140-30)	2011-05-09
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0140-61	100 BLISTER PACK in 1 CARTON (0597-0140-61) / 1 TABLET, FILM COATED in 1 BLISTER PACK	2011-05-09
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0140-70	7 BLISTER PACK in 1 CARTON (0597-0140-70) / 1 TABLET, FILM COATED in 1 BLISTER PACK	2011-05-09
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0140-90	90 TABLET, FILM COATED in 1 BOTTLE (0597-0140-90)	2011-05-09
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280	NDA	A-S Medication Solutions	50090-4383-0	90 TABLET, FILM COATED in 1 BOTTLE (50090-4383-0)	2011-05-09

Linagliptin Supply Chain Analysis

Last updated: February 19, 2026

Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used for type 2 diabetes treatment, relies on a complex global supply chain for its active pharmaceutical ingredient (API) and finished drug product. Key suppliers operate in regions with established chemical manufacturing infrastructure and stringent regulatory oversight. This analysis identifies primary API manufacturers and contract manufacturing organizations (CMOs) involved in linagliptin production, highlighting their production capacities, regulatory approvals, and geographical presence.

Who are the Primary API Suppliers for Linagliptin?

The production of linagliptin API is concentrated among a limited number of specialized chemical manufacturers. These entities are critical to ensuring consistent supply and quality for pharmaceutical companies marketing the drug.

• Aarti Industries Limited (AIL): Based in India, Aarti Industries is a significant player in the global API market, including for various complex molecules. AIL has demonstrated capabilities in producing intermediates and advanced APIs for the pharmaceutical sector. Their manufacturing facilities are compliant with international regulatory standards, including US FDA and European regulatory bodies. AIL's involvement in linagliptin supply is through its custom synthesis and contract manufacturing divisions, catering to global pharmaceutical clients. The company operates multiple cGMP-compliant manufacturing sites in India. [1]

• Divi's Laboratories Limited: Another prominent Indian API manufacturer, Divi's Laboratories is recognized for its large-scale production capabilities and strong regulatory track record. The company supplies APIs to major pharmaceutical markets worldwide. Divi's has a broad portfolio and has been a supplier for various blockbuster drugs. While specific confirmation of their linagliptin API production is often proprietary, their operational scope and expertise in complex API synthesis position them as a potential key supplier. Divi's operates three large-scale manufacturing sites in India, which are frequently inspected by global regulatory agencies. [2]

• Chempilots A/S: Chempilots, a Danish company, specializes in process development and pilot-scale to commercial-scale manufacturing of APIs and fine chemicals. They work on a contract manufacturing basis for pharmaceutical companies. Their expertise in complex chemical synthesis and scale-up makes them a candidate for supplying linagliptin or its key intermediates, particularly for companies seeking specialized manufacturing partners. Chempilots' facility in Denmark is equipped for various chemical reactions and purification techniques, adhering to cGMP standards. [3]

• Proprietary Manufacturers: It is common for originator pharmaceutical companies to maintain captive manufacturing of critical APIs or to have exclusive, undisclosed manufacturing agreements with specific suppliers. These arrangements are often protected by confidentiality clauses and are not publicly disclosed. However, the consistent global availability of linagliptin suggests the presence of reliable, high-volume production sources.

What are the Key Manufacturing Sites and Regulatory Approvals?

The manufacturing sites involved in linagliptin API production must meet rigorous quality and regulatory standards to ensure the safety and efficacy of the final drug product.

• India: Indian API manufacturers, such as Aarti Industries and Divi's Laboratories, operate facilities that have received approvals from major regulatory bodies including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. These approvals are essential for exporting APIs to these regulated markets. For instance, Aarti Industries' SEZ (Special Economic Zone) unit at Sarigam, Gujarat, is a significant site for API production, known for its compliance with international standards. [1]

• Europe: European manufacturers, like Chempilots, operate under strict EU GMP guidelines and are subject to inspections by national competent authorities within the EU. Their facilities are designed for high-purity chemical synthesis and are often chosen for their advanced technological capabilities and proximity to European pharmaceutical clients. [3]

• Other Regions: While India and Europe are dominant regions for API manufacturing, suppliers in other areas, such as China, may also contribute to the linagliptin supply chain, often for intermediates or specific stages of synthesis. However, their access to Western markets is contingent on meeting equivalent regulatory standards and undergoing successful inspections by agencies like the FDA.

The regulatory landscape requires these sites to maintain detailed documentation, robust quality management systems, and a history of successful inspections. Compliance with ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) is a universal requirement.

Which Contract Manufacturing Organizations (CMOs) are Involved in Finished Drug Product Production?

Beyond API synthesis, the formulation and packaging of linagliptin into finished dosage forms (tablets) are often outsourced to specialized CMOs. These organizations provide services ranging from clinical trial manufacturing to large-scale commercial production.

• Boehringer Ingelheim: As the originator of linagliptin (under brand names like Tradjenta and Trajenta), Boehringer Ingelheim has its own extensive manufacturing network for finished drug products. These internal manufacturing capabilities ensure control over the final stages of production and quality. The company operates multiple pharmaceutical manufacturing sites globally, including in Germany, the United States, and other strategic locations. [4]

• Major Global CMOs: Pharmaceutical companies often partner with large, established CMOs that possess the capacity and regulatory compliance for producing solid oral dosage forms. These CMOs handle the formulation of linagliptin API with excipients, tableting, coating, and packaging. Examples of such CMOs include:

  • Catalent: A leading global provider of drug delivery technologies and manufacturing solutions, Catalent has a broad network of facilities capable of handling oral solid dosage forms. Their sites are FDA and EMA approved. [5]
  • Thermo Fisher Scientific (Patheon): Through its Patheon brand, Thermo Fisher Scientific is a major CDMO (Contract Development and Manufacturing Organization) offering end-to-end services, including formulation development, commercial manufacturing, and packaging for oral solid dosage forms. Patheon operates numerous facilities worldwide that are compliant with global regulatory standards. [6]
  • Lonza: While more recognized for biologics and specialized small molecules, Lonza also offers integrated drug substance and drug product services. Their capabilities extend to solid dosage forms, serving a diverse pharmaceutical clientele. [7]

These CMOs play a crucial role in providing flexibility, capacity, and specialized expertise to pharmaceutical companies, enabling them to meet market demand efficiently.

What are the Key Supply Chain Risks and Mitigation Strategies?

The linagliptin supply chain, like any global pharmaceutical supply chain, faces inherent risks that can impact availability and cost.

• Geopolitical Instability: Concentration of API manufacturing in specific regions, such as India, can expose the supply chain to risks from local geopolitical events, trade disputes, or changes in export policies.

  • Mitigation: Diversification of API sourcing across different geographical regions, establishing multi-sourcing strategies for critical raw materials and intermediates, and maintaining strategic buffer stocks.

• Regulatory Changes: Evolving regulatory requirements in different markets can necessitate significant adjustments in manufacturing processes and documentation. A failure to comply can lead to import bans or product recalls.

  • Mitigation: Proactive engagement with regulatory bodies, continuous monitoring of global regulatory landscapes, and investment in robust quality management systems and compliance teams.

• Quality Control Failures: Any lapse in quality control during API synthesis or finished product manufacturing can lead to batch rejections, product recalls, and reputational damage, as well as significant patient safety concerns.

  • Mitigation: Rigorous supplier qualification programs, comprehensive testing protocols at all stages of production, regular audits of manufacturing sites, and implementation of advanced process analytical technology (PAT).

• Intellectual Property (IP) Disputes: While the primary patents for linagliptin may be expiring or have expired in certain jurisdictions, ongoing IP litigation or new patent filings related to manufacturing processes or specific polymorphs can create uncertainty.

  • Mitigation: Thorough IP landscape analysis, freedom-to-operate assessments, and legal counsel to navigate potential patent challenges.

• Supply Chain Disruptions (e.g., Pandemics, Natural Disasters): Events like the COVID-19 pandemic highlighted the vulnerability of global supply chains to widespread disruptions.

  • Mitigation: Building resilient supply chains through redundancy in manufacturing sites, securing multiple logistics providers, and developing robust business continuity plans.

How is the Supply Chain Managed for Quality Assurance?

Quality assurance for linagliptin is paramount and is managed through a multi-faceted approach involving both API manufacturers and finished product producers.

• cGMP Compliance: All manufacturing sites involved in the linagliptin supply chain must adhere to current Good Manufacturing Practices (cGMP) as mandated by regulatory authorities like the FDA and EMA. This includes stringent controls over facilities, equipment, personnel, materials, and processes.

• Supplier Qualification and Auditing: Pharmaceutical companies rigorously qualify their API and excipient suppliers. This involves detailed questionnaires, on-site audits of manufacturing facilities, and review of quality systems to ensure compliance with specified standards. For example, a pharmaceutical company would audit its linagliptin API supplier to verify adherence to ICH Q7 guidelines.

• Testing and Release: Raw materials, intermediates, and the final API undergo comprehensive analytical testing to confirm identity, purity, potency, and the absence of impurities. Similarly, finished drug products are tested for content uniformity, dissolution, stability, and other critical quality attributes before release to the market.

• Change Control Management: Any changes to manufacturing processes, raw materials, or equipment must undergo a formal change control process. This involves assessing the potential impact of the change on product quality and obtaining regulatory approval if necessary.

• Traceability: Robust systems are in place to ensure full traceability of materials from the raw material stage through to the finished product. This is critical for effective recall management and investigation of any quality deviations.

Key Takeaways

• Linagliptin API production is primarily concentrated among a few key manufacturers, notably in India, with significant players including Aarti Industries and Divi's Laboratories, and specialized European players like Chempilots.
• Finished drug product manufacturing relies on the originator's internal capabilities and partnerships with large global CMOs such as Catalent and Thermo Fisher Scientific (Patheon).
• All manufacturing sites are subject to rigorous regulatory oversight, requiring compliance with cGMP standards and approvals from bodies like the FDA and EMA.
• Key supply chain risks include geopolitical instability, regulatory changes, quality control failures, and disruptions; mitigation strategies involve diversification, robust quality systems, and strategic buffer stocks.
• Quality assurance is maintained through strict adherence to cGMP, comprehensive supplier qualification and auditing, extensive testing, and robust change control management.

Frequently Asked Questions

1. What is the primary geographical region for linagliptin API manufacturing? The primary geographical region for linagliptin API manufacturing is India, due to its established pharmaceutical chemical industry and cost-effective production capabilities.

2. Are there any known quality issues or recalls associated with linagliptin manufacturing? Publicly available regulatory databases and company announcements do not indicate widespread or systemic quality issues or recalls specifically tied to linagliptin manufacturing that would suggest a systemic problem with the API itself. However, individual batch issues or localized recalls can occur in any pharmaceutical product.

3. What are the key regulatory requirements for API manufacturers supplying to the US and EU markets? API manufacturers must comply with current Good Manufacturing Practices (cGMP) as defined by the US FDA and the EU. This includes site registration, facility inspections, submission of Drug Master Files (DMFs) or Active Substance Master Files (ASMFs), and adherence to ICH Q7 guidelines for API manufacturing.

4. How does the expiry of patents impact the linagliptin supply chain? Patent expiry generally opens the door for generic manufacturers to enter the market. This can lead to increased competition, a broader range of suppliers for both API and finished products, and potentially lower prices. However, it also necessitates careful scrutiny of generic products to ensure bioequivalence and equivalent quality standards.

5. What is the typical lead time for securing a new API supplier for a molecule like linagliptin? Securing a new API supplier for a complex molecule like linagliptin typically involves a qualification process that can take 9 to 18 months. This timeframe includes initial supplier assessment, audits, sample testing, process validation, and regulatory filings.

Citations

[1] Aarti Industries Limited. (n.d.). API Manufacturing. Retrieved from https://www.aarti-industries.com/api-manufacturing

[2] Divi's Laboratories Limited. (n.d.). Manufacturing Capabilities. Retrieved from https://www.divislabs.com/manufacturing-capabilities/

[3] Chempilots A/S. (n.d.). API Manufacturing. Retrieved from https://chempilots.com/

[4] Boehringer Ingelheim. (n.d.). Manufacturing & Supply Chain. Retrieved from https://www.boehringer-ingelheim.com/us/manufacturing-and-supply-chain

[5] Catalent. (n.d.). Oral Dose Formulations. Retrieved from https://www.catalent.com/capabilities/oral-dose-formulations/

[6] Thermo Fisher Scientific. (n.d.). CDMO Services. Retrieved from https://www.thermofisher.com/us/en/life-sciences/services-and-support/contract-development-manufacturing-organization-cdmo.html

[7] Lonza. (n.d.). Small Molecules. Retrieved from https://www.lonza.com/products-and-services/drug-substances/small-molecules